Havana, Feb 13 (ACN) Cuba continues the development of its biotechnology with the recent creation of the first national product that uses magnetic nanoparticles to extract ribonucleic acid (RNA) from the SARS-CoV-2 coronavirus.
According to Doctor of Science Angelina Díaz García, general director of the Center for Advanced Studies of Cuba, this is a technological milestone that promotes greater security in the detection of positive cases. In an interview with the Granma newspaper, Díaz García pointed out that this product has high sensitivity and the ability to concentrate samples, thus avoiding false negatives, a vital issue to cut the transmission of COVID-19 in Cuba.
The head of the CEA explained that the fully Cuban diagnostician was validated at the Pedro Kourí Institute of Tropical Medicine and was granted an Authorization for Use in Emergencies by the Center for State Control of Medicines, Equipment and Medical Devices. As main characteristics, this product shows 100 percent concordance with imported kits, and does not require a cold chain; In addition, it substitutes imports of key resources to contain the pandemic.
Despite the economic, commercial and financial blockade imposed by the United States on Cuba, Cuban biotechnology has produced the essential drugs for the care of COVID-19 in the country, including the four national vaccine candidates, Soberana 01, Soberana 02, Mambisa and Abdala.
Note: ACN is Cuban News Agency, founded in 1974. The CEA was founded by the first son of Fidel Castro, Fidel Castro Díaz-Balart.